GERN
Geron Corporation
Biotechnology · Healthcare · United States
1.51
close · 2026-08-28
value
47
cheaper than peers47
quality
54
stronger fundamentals54
ranked against
Biotechnology (commercial)
value
quality
151 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.81× | 78 |
| price to book | 4.44× | 51 |
| forward P/E | 37.75× | 20 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -22.0% | 70 |
| return on equity | -28.3% | 67 |
| revenue growth | 17.2% | 49 |
| debt to equity | 55.9% | 31 |
4 of 4 measures available
Facts
| market cap | $970M |
| free cash flow | -$78.4M |
| employees | 258 |
| first trade | 1996-07-31 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-18 |